Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Korean investigators disclose mTORC1 inhibitors

Nov. 18, 2019

Phase II study of AV-101 in major depressive disorder does not meet primary endpoint

Nov. 15, 2019

New mu-opioid receptor agonists identified at Sichuan Kelun-Biotech Biopharmaceutical

Nov. 15, 2019

Phase IIa study of THX-110 in obstructive sleep apnea meets primary endpoint

Nov. 14, 2019

Shanghai Leadopharma Technology presents antiepileptic compounds

Nov. 14, 2019

Sumitomo Dainippon Pharma patents mGlu2 receptor negative allosteric modulators

Nov. 14, 2019

New exploratory phase I/II study in Japan assesses NS-089 in Duchenne muscular dystrophy

Nov. 13, 2019

New P2X7 receptor antagonists identified at Shionogi

Nov. 13, 2019

FDA places on hold the phase I/II IGNITE DMD study of SGT-001

Nov. 13, 2019

Case study points to protective AD gene

Nov. 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...